Friday, 6 December 2013

NICE or Nasty

MS# Research New drug for MS in UK.So it is Amber for Alemtuzumab, Green for Aubagio does that make Sanofi see Red.

So not a great few months for Alemtuzumab, first the recommendation that Alemtuzumab is effectively a third line drug in the US and recently NICE have sat on the fence with a not enough information as leaked on the wire

When reviewing the evidence for alemtuzumab, the Appraisal Committee of NICE concluded that there were still questions to be answered. This is why they have requested more details from the manufacturer; to ensure that we have the information the Appraisal Committee needs to reach their conclusions."

They are not satisfied about cost-effectiveness so the ball is batted back into Sanofi's court, maybe for a bit of price adjustment.

On the plus side Aubagio has got the green light from NICE so now Beta interferon and Glaterimer acetate has an oral competitor.

Is it time for NICE to look at the bigger picture, rather than just cost of drug or are they doing UK PLC a favour?
Maybe more from ProfG when he gets back from his travels....

4 comments:

  1. How is new drug pricing sorted out in the UK? Do the drug companies tell NICE the exact figure they want to sell for? And when does this get communicated? Are there bargaining rounds?

    If Sanofi has already told NICE this figure can the public find out what it is?

    I know that NICE strictly speaking doesn't cover the whole of the UK - are prices the same across the UK?

    Thanks

    ReplyDelete
    Replies
    1. This is a good question. Campath was pulled from the market so it could be rebranded for MS. From what I could find there are about 8500 new cases of CLL/year which is what Campath was used to treat. I wonder why the manufacturer just didnt jack the price up of Campath to treat CLL?

      What is it about MS that allows these astronomical prices? Surley CLL is as rare as MS.

      Delete
    2. They pay the price and once you get extorted there is no way back you are not going to charge less for a drug that works better.

      Delete
    3. I think there is abit of bargaining. The nhs is a powerful buyer as it is buying for te whole country.
      However companies dont want this figure made public. There are list prices but the nhs may be able to knockout that down.
      I have heard of prices of a few drugs doing nice. Not as bad as i thought but maybe nice thinks differently.
      Prof g knows more of the process

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.